- Nxera wins $35m after Phase II schizophrenia trial success Pharmaceutical Technology
- Why Neurocrine Biosciences Stock Was Tumbling This Week The Motley Fool
- Neurocrine’s KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose Fierce Biotech
- Neurocrine’s mixed schizophrenia…